Hyperpigmented spots at fundus examination: a new ocular sign in Neurofibromatosis Type I.

Choroidal nodules Enhanced depth imaging OCT (EDI-OCT) Hyperpigmented spots (HSs) Indirect ophthalmoscopy Near-infrared reflectance (NIR) imaging OCT (NIR-OCT) Neurofibromatosis Type I (NF1) Rare diseases Ultra-wide field (UWF)

Journal

Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602

Informations de publication

Date de publication:
23 03 2021
Historique:
received: 30 11 2020
accepted: 09 03 2021
entrez: 24 3 2021
pubmed: 25 3 2021
medline: 22 6 2021
Statut: epublish

Résumé

Neurofibromatosis Type I (NF1), also termed von Recklinghausen disease, is a rare genetic disorder that is transmitted by autosomal dominant inheritance, with complete penetrance and variable expressivity. It is caused by mutation in the NF1 gene on chromosome 17 encoding for neurofibromin, a protein with oncosuppressive activity, and it is 50% sporadic or inherited. The disease is characterized by a broad spectrum of clinical manifestations, mainly involving the nervous system, the eye and skin, and a predisposition to develop multiple benign and malignant neoplasms. Ocular diagnostic hallmarks of NF1 include optic gliomas, iris Lisch nodules, orbital and eyelid neurofibromas, eyelid café-au-lait spots. Choroidal nodules and microvascular abnormalities have recently been identified as additional NF1-related ocular manifestations. The present study was designed to describe the features and clinical significance of a new sign related to the visual apparatus in NF-1, represented by hyperpigmented spots (HSs) of the fundus oculi. HSs were detected in 60 (24.1%) out of 249 patients with NF1, with a positive predictive value of 100% and a negative predictive value of 44.2%. None of the healthy subjects (150 subjects) showed the presence of HSs. HSs were visible under indirect ophthalmoscopy, ultra-wide field (UWF) pseudocolor imaging and red-only laser image, near-infrared reflectance (NIR)-OCT, but they were not appreciable on UWF green reflectance. The location and features of pigmentary lesions matched with the already studied NF1-related choroidal nodules. No significant difference was found between the group of patients (n = 60) with ocular HSs and the group of patients (n = 189) without ocular pigmented spots in terms of age, gender or severity grading of the disease. A statistically significant association was demonstrated between the presence of HSs and neurofibromas (p = 0.047), and between the presence of HSs and NF1-related retinal microvascular abnormalities (p = 0.017). We described a new ocular sign represented by HSs of the fundus in NF1. The presence of HSs was not a negative prognostic factor of the disease. Following multimodal imaging, we demonstrated that HSs and choroidal nodules were consistent with the same type of lesion, and simple indirect ophthalmoscopy allowed for screening of HSs in NF1.

Sections du résumé

BACKGROUND
Neurofibromatosis Type I (NF1), also termed von Recklinghausen disease, is a rare genetic disorder that is transmitted by autosomal dominant inheritance, with complete penetrance and variable expressivity. It is caused by mutation in the NF1 gene on chromosome 17 encoding for neurofibromin, a protein with oncosuppressive activity, and it is 50% sporadic or inherited. The disease is characterized by a broad spectrum of clinical manifestations, mainly involving the nervous system, the eye and skin, and a predisposition to develop multiple benign and malignant neoplasms. Ocular diagnostic hallmarks of NF1 include optic gliomas, iris Lisch nodules, orbital and eyelid neurofibromas, eyelid café-au-lait spots. Choroidal nodules and microvascular abnormalities have recently been identified as additional NF1-related ocular manifestations. The present study was designed to describe the features and clinical significance of a new sign related to the visual apparatus in NF-1, represented by hyperpigmented spots (HSs) of the fundus oculi.
RESULTS
HSs were detected in 60 (24.1%) out of 249 patients with NF1, with a positive predictive value of 100% and a negative predictive value of 44.2%. None of the healthy subjects (150 subjects) showed the presence of HSs. HSs were visible under indirect ophthalmoscopy, ultra-wide field (UWF) pseudocolor imaging and red-only laser image, near-infrared reflectance (NIR)-OCT, but they were not appreciable on UWF green reflectance. The location and features of pigmentary lesions matched with the already studied NF1-related choroidal nodules. No significant difference was found between the group of patients (n = 60) with ocular HSs and the group of patients (n = 189) without ocular pigmented spots in terms of age, gender or severity grading of the disease. A statistically significant association was demonstrated between the presence of HSs and neurofibromas (p = 0.047), and between the presence of HSs and NF1-related retinal microvascular abnormalities (p = 0.017).
CONCLUSIONS
We described a new ocular sign represented by HSs of the fundus in NF1. The presence of HSs was not a negative prognostic factor of the disease. Following multimodal imaging, we demonstrated that HSs and choroidal nodules were consistent with the same type of lesion, and simple indirect ophthalmoscopy allowed for screening of HSs in NF1.

Identifiants

pubmed: 33757576
doi: 10.1186/s13023-021-01773-w
pii: 10.1186/s13023-021-01773-w
pmc: PMC7986306
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

147

Références

Indian J Ophthalmol. 2019 Dec;67(12):2101-2103
pubmed: 31755475
BMC Ophthalmol. 2014 Nov 25;14:146
pubmed: 25424184
Pigment Cell Res. 2007 Feb;20(1):61-9
pubmed: 17250549
Surv Ophthalmol. 2018 Jul - Aug;63(4):518-533
pubmed: 29080631
Graefes Arch Clin Exp Ophthalmol. 2018 Sep;256(9):1789-1790
pubmed: 29860546
Tohoku J Exp Med. 1976 Mar;118(3):255-73
pubmed: 817416
Lancet. 2000 Sep 16;356(9234):988-92
pubmed: 11041400
Pigment Cell Melanoma Res. 2013 Sep;26(5):634-45
pubmed: 23815504
Arch Ophthalmol. 1965 May;73:696-9
pubmed: 14281990
Ophthalmologica. 1998;212(2):99-104
pubmed: 9486548
Arch Ophthalmol. 1982 Dec;100(12):1939-41
pubmed: 6816197
Eye Brain. 2020 Oct 21;12:119-127
pubmed: 33117026
Pigment Cell Res. 2005 Feb;18(1):13-24
pubmed: 15649148
Hum Genet. 2004 Feb;114(3):284-90
pubmed: 14605872
Arch Dermatol Res. 2006 Apr;297(10):439-49
pubmed: 16479403
Graefes Arch Clin Exp Ophthalmol. 2015 Dec;253(12):2121-7
pubmed: 25690981
Soc Sci Med. 1996 Jan;42(1):99-109
pubmed: 8745111
Graefes Arch Clin Exp Ophthalmol. 2018 Feb;256(2):307-311
pubmed: 29290016
Clin Ter. 2019 Jan-Feb;170(1):e4-e9
pubmed: 30789191
Br J Ophthalmol. 2009 Jan;93(1):79-82
pubmed: 18829635
Am J Ophthalmol. 2008 Oct;146(4):496-500
pubmed: 18639219
Br J Ophthalmol. 2011 Aug;95(8):1134-9
pubmed: 20881028
Genet Med. 2010 Jan;12(1):1-11
pubmed: 20027112
Br J Ophthalmol. 2019 Nov;103(11):1590-1594
pubmed: 30705042
Arch Pathol Lab Med. 1997 Feb;121(2):139-43
pubmed: 9126041
Oncotarget. 2014 Aug 15;5(15):5873-92
pubmed: 25026295
Indian J Ophthalmol. 2018 Apr;66(4):586-588
pubmed: 29582830
Arch Ophthalmol. 1977 Nov;95(11):1990-2
pubmed: 411462
J Eur Acad Dermatol Venereol. 2004 May;18(3):342-4
pubmed: 15096151
Glia. 2018 Mar;66(3):465-476
pubmed: 29124786
Case Rep Ophthalmol. 2017 Apr 10;8(1):214-220
pubmed: 28512424
J Neurobiol. 1995 Aug;27(4):535-52
pubmed: 7561832
Retina. 2018 Mar;38(3):585-593
pubmed: 28248826
Arch Neurol. 1988 May;45(5):575-8
pubmed: 3128965
Birth Defects Orig Artic Ser. 1977;13(3C):131-8
pubmed: 407957
Appl Opt. 1989 Mar 15;28(6):1061-77
pubmed: 20548621

Auteurs

Antonietta Moramarco (A)

Department of Sense Organs, Sapienza University of Rome, Policlinico Umberto I, Viale del Policlinico 155, 00161, Rome, Italy.

Fabiana Mallone (F)

Department of Sense Organs, Sapienza University of Rome, Policlinico Umberto I, Viale del Policlinico 155, 00161, Rome, Italy.

Marta Sacchetti (M)

Department of Sense Organs, Sapienza University of Rome, Policlinico Umberto I, Viale del Policlinico 155, 00161, Rome, Italy.

Luca Lucchino (L)

Department of Sense Organs, Sapienza University of Rome, Policlinico Umberto I, Viale del Policlinico 155, 00161, Rome, Italy.

Emanuele Miraglia (E)

Department of Dermatology and Venereology, Sapienza University of Rome, Policlinico Umberto I, Rome, Italy.

Vincenzo Roberti (V)

Department of Dermatology and Venereology, Sapienza University of Rome, Policlinico Umberto I, Rome, Italy.

Alessandro Lambiase (A)

Department of Sense Organs, Sapienza University of Rome, Policlinico Umberto I, Viale del Policlinico 155, 00161, Rome, Italy. alessandro.lambiase@uniroma1.it.

Sandra Giustini (S)

Department of Dermatology and Venereology, Sapienza University of Rome, Policlinico Umberto I, Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH